## **GIBSON DUNN**

## Gibson Dunn Advises Jade Biosciences on Merger with Aerovate Therapeutics, Inc. and Concurrent Private Placement

Firm News | October 31, 2024

Gibson Dunn is advising Jade Biosciences on its merger with Aerovate Therapeutics, Inc. and the concurrent \$300 million private placement of shares of its common stock and prefunded warrants to a syndicate of healthcare investors. The Gibson Dunn corporate team includes partners Ryan Murr, Branden Berns and Chris Trester and associates Evan Shepherd and Candice Johnson.

## **Related People**

Ryan A. Murr

Branden C. Berns

Chris W. Trester

Evan Shepherd

Candice D. Johnson

## **Related Capabilities**

**Mergers and Acquisitions** 

Life Sciences